Reduced vascular responsiveness to adiponectin in hyperlipidemic rats-mechanisms and significance

Journal of Molecular and Cellular Cardiology

Volumn 49, Issue 3, 2010, Pages 508-515

  Li, Rong ^a   Xu, Ming ^a   Wang, Xiaoliang ^a   Wang, Yajing ^b   Lau, Wayne Bond ^b   Yuan, Yuexing ^b   Yi, Wei ^a   Wei, Xuefeng ^a   Lopez, Bernard L ^b   Christopher, Theodore A ^b   Wang, Xiao Ming ^a   Ma, Xin Liang ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Adiponectin; Cytokines; Dyslipidemia; Obesity; Vascular injury

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD VESSEL INJURY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; LIPID DIET; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; VASODILATATION;

ANIMALIA; RATTUS;

EID: 77955278430     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.03.002     Document Type: Article

References (35)

1. Krumholz H.M., Wang Y., Chen J., Drye E.E., Spertus J.A., Ross J.S., et al. Reduction in acute myocardial infarction mortality in the United States: Risk-Standardized Mortality Rates From 1995-2006. JAMA 2009, 302:767-773.
2. Grundy S.M., Brewer H.B., Cleeman J.I., Smith S.C., Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004, 109:433-438. for the Conference Participants.
3. Cooper-Dehoff R.M., Pepine C.J. Metabolic syndrome and cardiovascular disease: challenges and opportunities. Clin Cardiol 2007, 30:593-597.
4. Heusch G. Obesity-a risk factor or a RISK factor for myocardial infarction?. Br J Pharmacol 2006, 149:1-3.
5. Ouchi N., Shibata R., Walsh K. Cardioprotection by adiponectin. Trends Cardiovasc Med 2006, 16:141-146.
6. Zhu W., Cheng K.K., Vanhoutte P.M., Lam K.S., Xu A. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci (Lond) 2008, 114:361-374.
7. Goldstein B.J., Scalia R.G., Ma X.L. Protective vascular and myocardial effects of adiponectin. Nat Clin Pract Cardiovasc Med 2009, 6:27-35.
8. Rabin K.R., Kamari Y., Avni I., Grossman E., Sharabi Y. Adiponectin: linking the metabolic syndrome to its cardiovascular consequences. Expert Rev Cardiovasc Ther 2005, 3:465-471.
9. Kumada M., Kihara S., Sumitsuji S., Kawamoto T., Matsumoto S., Ouchi N., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003, 23:85-89.
10. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000, 20:1595-1599.
11. Semple R.K., Halberg N.H., Burling K., Soos M.A., Schraw T., Luan J., et al. Paradoxical elevation of high-molecular weight adiponectin in acquired extreme insulin resistance due to insulin receptor antibodies. Diabetes 2007, 56:1712-1717.
12. Kanety H., Hemi R., Ginsberg S., Pariente C., Yissachar E., Barhurdar E., et al. Total and high molecular weight adiponectin are elevated in patients with Laron syndrome despite marked obesity. Eur J Endocrinol 2009, 161(6):837-844.
13. Rodriguez A., Catalan V., Becerril S., Gil M.J., Mugueta C., Gomez-Ambrosi J., et al. Impaired adiponectin-AMPK signalling in insulin-sensitive tissues of hypertensive rats. Life Sci 2008, 83:540-549.
14. Bruce C.R., Mertz V.A., Heigenhauser G.J., Dyck D.J. The stimulatory effect of globular adiponectin on insulin-stimulated glucose uptake and fatty acid oxidation is impaired in skeletal muscle from obese subjects. Diabetes 2005, 54:3154-3160.
15. Chen M.B., McAinch A.J., Macaulay S.L., Castelli L.A., O'Brien P.E., Dixon J.B., et al. Impaired activation of AMP-kinase and fatty acid oxidation by globular adiponectin in cultured human skeletal muscle of obese type 2 diabetics. J Clin Endocrinol Metab 2005, 90:3665-3672.
16. Mullen K.L., Smith A.C., Junkin K.A., Dyck D.J. Globular adiponectin resistance develops independently of impaired insulin-stimulated glucose transport in soleus muscle from high-fat-fed rats. Am J Physiol Endocrinol Metab 2007, 293:E83-E90.
17. Lin H.V., Kim J.Y., Pocai A., Rossetti L., Shapiro L., Scherer P.E., et al. Adiponectin resistance exacerbates insulin resistance in insulin receptor transgenic/knockout mice. Diabetes 2007, 56:1969-1976.
18. Mullen K.L., Pritchard J., Ritchie I., Snook L.A., Chabowski A., Bonen A., et al. Adiponectin resistance precedes the accumulation of skeletal muscle lipids and insulin resistance in high-fat-fed rats. Am J Physiol Regul Integr Comp Physiol 2009, 296:R243-R251.
19. Xi W., Satoh H., Kase H., Suzuki K., Hattori Y. Stimulated HSP90 binding to eNOS and activation of the PI3-Akt pathway contribute to globular adiponectin-induced NO production: vasorelaxation in response to globular adiponectin. Biochem Biophys Res Commun 2005, 332:200-205.
20. Cao Y., Tao L., Yuan Y., Jiao X., Lau W.B., Wang Y., et al. Endothelial dysfunction in adiponectin deficiency and its mechanisms involved. J Mol Cell Cardiol 2009, 46:413-419.
21. Garvey E.P., Oplinger J.A., Furfine E.S., Kiff R.J., Laszlo F., Whittle B.J., et al. 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo. J Biol Chem 1997, 272:4959-4963.
22. Wang Y., Gao E., Tao L., Lau W.B., Yuan Y., Goldstein B.J., et al. AMP-activated protein kinase deficiency enhances myocardial ischemia/reperfusion injury but has minimal effect on the antioxidant/antinitrative protection of adiponectin. Circulation 2009, 119:835-844.
23. Wu X., Mahadev K., Fuchsel L., Ouedraogo R., Xu S.Q., Goldstein B.J. Adiponectin suppresses IkappaB kinase activation induced by tumor necrosis factor-alpha or high glucose in endothelial cells: role of cAMP and AMP kinase signaling. Am J Physiol Endocrinol Metab 2007, 293:E1836-E1844.
24. Bucala R., Makita Z., Vega G., Grundy S., Koschinsky T., Cerami A., et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994, 91:9441-9445.
25. Munzel D., Lehle K., Haubner F., Schmid C., Birnbaum D.E., Preuner J.G. Impact of diabetic serum on endothelial cells: an in-vitro-analysis of endothelial dysfunction in diabetes mellitus type 2. Biochem Biophys Res Commun 2007, 362:238-244.
26. Kadowaki T., Yamauchi T., Kubota N., Hara K., Ueki K., Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006, 116:1784-1792.
27. Ouchi N., Kihara S., Arita Y., Okamoto Y., Maeda K., Kuriyama H., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000, 102:1296-1301.
28. Ohashi K., Kihara S., Ouchi N., Kumada M., Fujita K., Hiuge A., et al. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 2006, 47:1108-1116.
29. Zhou L., Deepa S.S., Etzler J.C., Ryu J., Mao X., Fang Q., et al. Adiponectin activates AMP-activated protein kinase in muscle cells via APPL1/LKB1-dependent and phospholipase C/Ca2+/Ca2+/calmodulin-dependent protein kinase kinase-dependent pathways. J Biol Chem 2009, 284:22426-22435.
30. Chen H., Montagnani M., Funahashi T., Shimomura I., Quon M.J. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003, 278:45021-45026.
31. Bonnard C., Durand A., Vidal H., Rieusset J. Changes in adiponectin, its receptors and AMPK activity in tissues of diet-induced diabetic mice. Diab Metab 2008, 34:52-61.
32. Lo J., Bernstein L.E., Canavan B., Torriani M., Jackson M.B., Ahima R.S., et al. Effects of TNF-alpha neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome. Am J Physiol Endocrinol Metab 2007, 293:E102-E109.
33. Higuchi A., Ohashi K., Kihara S., Walsh K., Ouchi N. Adiponectin suppresses pathological microvessel formation in retina through modulation of tumor necrosis factor-{alpha} expression. Circ Res 2009, 104:1058-1065.
34. Saito Y., Fujioka D., Kawabata K.I., Kobayashi T., Yano T., Nakamura T., et al. Statin reverses reduction of adiponectin receptor expression in infarcted heart and in TNF{alpha}-treated cardiomyocytes in association with improved glucose uptake. Am J Physiol Heart Circ Physiol 2007, 293:H3490-H3497.
35. Tao L., Gao E., Jiao X., Yuan Y., Li S., Christopher T.A., et al. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 2007, 115:1408-1416.